Related Experiment Video

Updated: Jun 14, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic

Marion David1, Estelle Wannecq, Françoise Descotes

  • 1INSERM, U664, Lyon, France.

Plos One
|March 23, 2010
PubMed
Abstract

Insights

Autotaxin (ATX) expression in cancer cells drives osteolytic bone metastasis formation by promoting tumor growth and osteoclast differentiation. Targeting the ATX/lysophosphatidic acid (LPA) pathway offers a potential therapeutic strategy for bone metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis

Background:

  • Bone metastases are common in breast cancer, and current treatments are palliative.
  • Autotaxin (ATX) is implicated in cancer progression and metastasis.
  • Platelet-derived lysophosphatidic acid (LPA) promotes osteolytic bone metastasis.

Purpose of the Study:

  • To investigate the role of ATX in osteolytic bone metastasis formation.
  • To characterize the mechanisms by which ATX influences bone metastasis.

Main Methods:

  • Genetically modified breast cancer cells (MDA-B02/ATX and 4T1) were used in mouse models.
  • ATX expression was manipulated (forced expression and silencing).
  • In vitro assays assessed osteoclast differentiation and the effect of ATX inhibition.

Main Results:

  • Forced ATX expression enhanced bone metastasis, bone loss, and osteoclast activity.
  • ATX silencing in 4T1 cells reduced bone metastasis and osteoclast numbers.
  • ATX and LPA promoted osteoclast differentiation in vitro, which was blocked by an ATX inhibitor.

Conclusions:

  • Cancer cell-expressed ATX is a key driver of osteolytic bone metastasis.
  • LPA directly stimulates cancer growth, metastasis, and osteoclast differentiation.
  • Targeting the ATX/LPA axis presents a novel therapeutic avenue for bone metastasis.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Autocrine Signaling01:01

Autocrine Signaling

Autocrine signaling is one of the many signaling mechanisms that function inside multicellular organisms to carry out intercellular communication. In this type of signaling mechanism, the same cell that secretes an extracellular signaling molecule also expresses the receptors to bind and respond to that signaling molecule.
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...